ArticleClinical lung cancer2025
Factors Associated With Local Control and Toxicity of Hypofractionated Radiotherapy for Early and Late-Stage Ultracentral Lung Tumors.
Article in Clinical lung cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundTreating ultracentral tumors near critical mediastinal structures is challenging due to severe toxicity risks. This retrospective study evaluates the safety and efficacy of hypofractionated body radiotherapy (HFRT) for ultracentral tumors at a single institution.
methodsUltracentral tumors were defined as those invading, abutting, or having an overlapping planning target volume with the proximal bronchial tree (PBT), heart, great vessels, or esophagus. Patients with primary lung cancer or metastases from nonlung primaries, and received HFRT (6-15 fractions) or stereotactic body radiotherapy (SBRT, ≤5 fractions) were included. Radiation-associated toxicities were recorded. Outcomes included overall survival (OS), progression-free survival (PFS), and local control (LC). Prognostic factors were analyzed using Cox regression analysis.
resultsEighty-six patients with ultracentral tumors underwent 94 treatment courses (69 SBRT, 25 HFRT) between 2014 and 2023. Radiation pneumonitis (RP), pneumonia, and cardiotoxicities developed in 39.3%, 13.9%, and 9.6% of treatments, respectively. One patient experienced grade 3 pulmonary hemorrhage, with no cases of airway fistula or necrosis. Median follow-up was 17.9 months with 1-year and 2-year OS rates of 78.7% and 65.6%, and LC rates of 93.5% and 84.0%, respectively. BED
conclusionsHFRT can be safely administered to ultracentral tumors with excellent local control and low toxicity. Further research is needed to optimize treatment strategies and investigate associations between RP and increased local failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.